ICOSABUTATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H38O3
Molecular Weight	374.5567
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	5
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(O)=O

InChI

InChIKey=VOGXDRFFBBLZBT-AAQCHOMXSA-N

InChI=1S/C24H38O3/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-27-23(4-2)24(25)26/h5-6,8-9,11-12,14-15,17-18,23H,3-4,7,10,13,16,19-22H2,1-2H3,(H,25,26)/b6-5-,9-8-,12-11-,15-14-,18-17-

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26892135 | https://www.northseatherapeutics.com/news/potential-of-icosabutate-as-a-novel-approach-to-the-treatment-of-nash-highlighted-in-late-breaker-at-the-international-liver-congresstm-2018/

Icosabutate (also known as PRC-4016 or NST-4016), a cholesterol ester transfer protein inhibitor was developed by NorthSea Therapeutics for the treatment of combined dyslipidemias and hypertriglyceridemia. Icosabutate successfully completed phase II clinical trial for hypertriglyceridemic subjects, where was studied the drug efficacy and safety. In April 2018 NorthSea Therapeutics announced that its lead product, icosabutate would be further developed as an effective and safe therapeutic approach to treating both non-alcoholic steatohepatitis and its associated comorbidities.

Originator

Approval Year

PubMed

Title	Date	PubMed
Icosabutate, a More Potent Form of Omega 3 Fatty Acids, Shows Promise in Lowering Triglycerides.	2016	27160264
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.	2016	27160246
Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.	2016 Jan-Feb	26892135

Patents

Sample Use Guides

In Vivo Use Guide

After a 6-8 week run-in period, men and women with TG levels ≥ 500 mg/dL and ≤ 1500 mg/dL were randomized to double-blind treatment with placebo or icosabutate 600 mg for 12 weeks

Route of Administration: Oral

Name

Type

Language

ICOSABUTATE

Official Name

English

PRB-01022

Code

English

Icosabutate [WHO-DD]

Common Name

English

BUTANOIC ACID, 2-((5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-EICOSAPENTAEN-1-YLOXY)-

Systematic Name

English

NST-4016

Code

English

rac-2-[(5Z,8Z,11Z,14Z,17Z)Icosa-5,8,11,14,17-pentaen-1-yloxy]butanoic acid

Systematic Name

English

ICOSABUTATE [USAN]

Common Name

English

icosabutate [INN]

Common Name

English

PRC-4016

Code

English

Code System Code Type Description

DRUG BANK

DB12990